Prevalence of Antibody against Non‐A, non‐B Hepatitis Virus in Japanese Patients with Hepatocellular Carcinoma

Showgo Ohkoshi; Hideo Kojima; Hironobu Tawaraya; Tohru Miyajima; Tomoteru Kamimura; Hitoshi Asakura; Akira Satoh; Shinichi Hirose; Makoto Hijikata; Nobuyuki Kato; Kunitada Shimotohno

doi:10.1111/j.1349-7006.1990.tb02605.x

Prevalence of Antibody against Non‐A, non‐B Hepatitis Virus in Japanese Patients with Hepatocellular Carcinoma

Showgo Ohkoshi, Hideo Kojima, Hironobu Tawaraya, Tohru Miyajima, Tomoteru Kamimura, Hitoshi Asakura, Akira Satoh, Shinichi Hirose, Makoto Hijikata, Nobuyuki Kato, Kunitada Shimotohno

Research output: Contribution to journal › Article › peer-review

85 Citations (Scopus)

Abstract

Antibodies against a possible causative agent of non‐A, non‐B hepatitis, hepatitis C virus (HCV), in Japanese patients with hepatocellular carcinoma were analyzed using the enzyme‐linked immunosorbent assay (ELISA) system from Ortho Diagnostic Systems, Japan. Fifty of 58 cases of hepatitis B virus surface antigen (HBsAg)‐negative hepatocellular carcinoma were positive for the antibody (86%) and 8 of 42 cases of HBsAg‐positive hepatocellular carcinoma were positive (19%). Among patients with HBsAg‐negative hepatocellular carcinoma, the prevalence of the antibody was greater among those who had received a blood transfusion (97%) than among those with no history of transfusion (70%). Only 3 of 54 patients with cancers other than hepatocellular carcinoma were found to be antibody‐positive (5.6%) and all three patients had a history of blood transfusion. These results show a close relationship between the presence of anti‐HCV antibody and HBsAg‐negative hepatocellular carcinoma in Japan.

Original language	English
Pages (from-to)	550-553
Number of pages	4
Journal	Japanese Journal of Cancer Research
Volume	81
Issue number	6-7
DOIs	https://doi.org/10.1111/j.1349-7006.1990.tb02605.x
Publication status	Published - Jun 1990
Externally published	Yes

Keywords

Antibody
Hepatitis C virus
Hepatocellular carcinoma
Non‐A, non‐B hepatitis virus

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1349-7006.1990.tb02605.x

Cite this

Ohkoshi, S., Kojima, H., Tawaraya, H., Miyajima, T., Kamimura, T., Asakura, H., Satoh, A., Hirose, S., Hijikata, M., Kato, N., & Shimotohno, K. (1990). Prevalence of Antibody against Non‐A, non‐B Hepatitis Virus in Japanese Patients with Hepatocellular Carcinoma. Japanese Journal of Cancer Research, 81(6-7), 550-553. https://doi.org/10.1111/j.1349-7006.1990.tb02605.x

Ohkoshi, S, Kojima, H, Tawaraya, H, Miyajima, T, Kamimura, T, Asakura, H, Satoh, A, Hirose, S, Hijikata, M, Kato, N & Shimotohno, K 1990, 'Prevalence of Antibody against Non‐A, non‐B Hepatitis Virus in Japanese Patients with Hepatocellular Carcinoma', Japanese Journal of Cancer Research, vol. 81, no. 6-7, pp. 550-553. https://doi.org/10.1111/j.1349-7006.1990.tb02605.x

@article{9ec156e9704542fdb8f81a393a96f30b,

title = "Prevalence of Antibody against Non‐A, non‐B Hepatitis Virus in Japanese Patients with Hepatocellular Carcinoma",

abstract = "Antibodies against a possible causative agent of non‐A, non‐B hepatitis, hepatitis C virus (HCV), in Japanese patients with hepatocellular carcinoma were analyzed using the enzyme‐linked immunosorbent assay (ELISA) system from Ortho Diagnostic Systems, Japan. Fifty of 58 cases of hepatitis B virus surface antigen (HBsAg)‐negative hepatocellular carcinoma were positive for the antibody (86%) and 8 of 42 cases of HBsAg‐positive hepatocellular carcinoma were positive (19%). Among patients with HBsAg‐negative hepatocellular carcinoma, the prevalence of the antibody was greater among those who had received a blood transfusion (97%) than among those with no history of transfusion (70%). Only 3 of 54 patients with cancers other than hepatocellular carcinoma were found to be antibody‐positive (5.6%) and all three patients had a history of blood transfusion. These results show a close relationship between the presence of anti‐HCV antibody and HBsAg‐negative hepatocellular carcinoma in Japan.",

keywords = "Antibody, Hepatitis C virus, Hepatocellular carcinoma, Non‐A, non‐B hepatitis virus",

author = "Showgo Ohkoshi and Hideo Kojima and Hironobu Tawaraya and Tohru Miyajima and Tomoteru Kamimura and Hitoshi Asakura and Akira Satoh and Shinichi Hirose and Makoto Hijikata and Nobuyuki Kato and Kunitada Shimotohno",

year = "1990",

month = jun,

doi = "10.1111/j.1349-7006.1990.tb02605.x",

language = "English",

volume = "81",

pages = "550--553",

journal = "Cancer Science",

issn = "1347-9032",

publisher = "Wiley-Blackwell",

number = "6-7",

}

TY - JOUR

T1 - Prevalence of Antibody against Non‐A, non‐B Hepatitis Virus in Japanese Patients with Hepatocellular Carcinoma

AU - Ohkoshi, Showgo

AU - Kojima, Hideo

AU - Tawaraya, Hironobu

AU - Miyajima, Tohru

AU - Kamimura, Tomoteru

AU - Asakura, Hitoshi

AU - Satoh, Akira

AU - Hirose, Shinichi

AU - Hijikata, Makoto

AU - Kato, Nobuyuki

AU - Shimotohno, Kunitada

PY - 1990/6

Y1 - 1990/6

N2 - Antibodies against a possible causative agent of non‐A, non‐B hepatitis, hepatitis C virus (HCV), in Japanese patients with hepatocellular carcinoma were analyzed using the enzyme‐linked immunosorbent assay (ELISA) system from Ortho Diagnostic Systems, Japan. Fifty of 58 cases of hepatitis B virus surface antigen (HBsAg)‐negative hepatocellular carcinoma were positive for the antibody (86%) and 8 of 42 cases of HBsAg‐positive hepatocellular carcinoma were positive (19%). Among patients with HBsAg‐negative hepatocellular carcinoma, the prevalence of the antibody was greater among those who had received a blood transfusion (97%) than among those with no history of transfusion (70%). Only 3 of 54 patients with cancers other than hepatocellular carcinoma were found to be antibody‐positive (5.6%) and all three patients had a history of blood transfusion. These results show a close relationship between the presence of anti‐HCV antibody and HBsAg‐negative hepatocellular carcinoma in Japan.

AB - Antibodies against a possible causative agent of non‐A, non‐B hepatitis, hepatitis C virus (HCV), in Japanese patients with hepatocellular carcinoma were analyzed using the enzyme‐linked immunosorbent assay (ELISA) system from Ortho Diagnostic Systems, Japan. Fifty of 58 cases of hepatitis B virus surface antigen (HBsAg)‐negative hepatocellular carcinoma were positive for the antibody (86%) and 8 of 42 cases of HBsAg‐positive hepatocellular carcinoma were positive (19%). Among patients with HBsAg‐negative hepatocellular carcinoma, the prevalence of the antibody was greater among those who had received a blood transfusion (97%) than among those with no history of transfusion (70%). Only 3 of 54 patients with cancers other than hepatocellular carcinoma were found to be antibody‐positive (5.6%) and all three patients had a history of blood transfusion. These results show a close relationship between the presence of anti‐HCV antibody and HBsAg‐negative hepatocellular carcinoma in Japan.

KW - Antibody

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Non‐A, non‐B hepatitis virus

UR - http://www.scopus.com/inward/record.url?scp=0025309010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025309010&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.1990.tb02605.x

DO - 10.1111/j.1349-7006.1990.tb02605.x

M3 - Article

C2 - 2169469

AN - SCOPUS:0025309010

VL - 81

SP - 550

EP - 553

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 6-7

ER -

Prevalence of Antibody against Non‐A, non‐B Hepatitis Virus in Japanese Patients with Hepatocellular Carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this